Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by <i>SLC22A2</i> gene). The effect of the genetic variant <i>SLC22A2</i> 808C>A on dolutegravir disc...

Full description

Bibliographic Details
Main Authors: Jessica Cusato, Alberto Borghetti, Elisabetta Teti, Maurizio Milesi, Maria Cristina Tettoni, Stefano Bonora, Mattia Trunfio, Antonio D’Avolio, Mirko Compagno, Simona Di Giambenedetto, Giovanni Di Perri, Andrea Calcagno
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Metabolites
Subjects:
psychiatric symptoms
depression
dolutegravir
pharmacogenetics
discontinuation
Online Access:https://www.mdpi.com/2218-1989/12/12/1202

Internet

https://www.mdpi.com/2218-1989/12/12/1202

Similar Items